Blueprint Medicines, a start-up cancer-therapeutics company based in Cambridge, Massachusetts, is to recruit up to 20 researchers. In April, the firm secured US$40 million in venture capital, the largest first-round financing deal in 2011 so far for a life-sciences company, says the US National Venture Capital Association in Arlington, Virginia. Chris Varma, co-founder of Blueprint, says that the start-up is seeking early-career and established medicinal chemists, cell and structural biologists, and bioinformaticians to help discover genomics-based therapies.